groups. The difference for residing in Foster Care was no longer seen at 12 months and beyond. CONCLUSION: This is one of the largest prospective studies to date analyzing long-term outcome of NAS newborns. These data demonstrate that a significant number of infants have abnormalities in testing that extends to at least 3 years of age. Foster Care may be a factor up to 12 months of age. Continued long-term follow-up is needed in these children to determine the full effect of chronic opioid exposure in-utero. Additionally, torticollis is common with right versus left sided rates being similar to rates of right-handedness to left-handedness. The pathophysiology for this needs further investigation.
566 Co-prescription of opioids and psychotropics among commercially insured US pregnant women and neonatal abstinence syndrome 2 University of Utah, Salt Lake City, UT OBJECTIVE: In the US the incidence of neonatal abstinence syndrome (NAS) is rising, and both maternal opioid and psychotropic use have been implicated as independent risk factors. Our objective was to determine the association between maternal co-prescription to opioid and psychotropic medications and NAS compared to either opioids or psychotropics alone. STUDY DESIGN: A retrospective observational study of the [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] [2015] MarketScan database, a nationwide de-identified population of commercial insurance beneficiaries. Our primary outcome was NAS identified by diagnosis codes (ICD-9 779.5x). Our exposure was outpatient opioid and psychotropic co-prescription compared to psychotropics only and opioids only. Among co-prescribed women, we conducted subgroup analyses among women prescribed >1 type of psychotropic, opioid prescription >30 days (i.e. chronic use), coprescription during the same trimester, and prescription of gabapentin and benzodiazepine. Multivariable logistic regression models were used, adjusting for age, insurance type, dependent children, diagnosis codes for alcohol, tobacco, or illicit drug use, and US region to determine the association between maternal co-prescription and NAS.
RESULTS:
We identified 958,274 pregnant women with live births >21 weeks; 94,588 (9.9%) had only an opioid prescription, 55,285 (5.8%) had only a psychotropic prescription, and 19,884 (2.1%) had both. The frequency of NAS was significantly higher with co-prescription compared to either opioids or psychotropics (1.3% vs. 0.2%, 0.2%; p<0.0001); and increased further among subgroups of co-prescribed women. The adjusted odds of NAS for infants with mothers with co-prescription was 3.95 (95% CI: 3.22-4.85) compared to opioids only, and 6.10 (95% CI: 4.73-7.88) compared to psychotropics only (Table 1) . Among co-prescribed women, opioid prescription >30 days (vs. 30 days), and co-prescription during the same trimester (vs. no trimester with co-prescription) further increased the adjusted odds of NAS (Table 2) . CONCLUSION: Among commercially insured US pregnant women, compared to either prescription type alone, co-prescription of opioids and psychotropic medications is associated with significantly greater risk of NAS. These findings suggest that the evidence-based use of opioids and psychotropics for maternal pain and mental health disorders could decrease the rising rate of NAS.
567 Co-prescription of opioids and psychotropics among commercially insured US pregnant women and adverse pregnancy outcome University of North Carolina, Chapel Hill, NC, 2 University of Utah, Salt Lake City, UT OBJECTIVE: Both opioid or psychotropic prescription during pregnancy are independently associated with adverse pregnancy outcomes; however, the impact of co-prescription of opioids and psychotropics is not known. Our objective was to estimate the association between co-prescription of opioid and psychotropic medications in pregnancy and perinatal outcomes, including preterm birth (PTB) <37 weeks' gestation, cesarean delivery, and 
